Abstract: The invention relates to compounds of formula (I), and to their therapeutic use in the treatment of cancer: Wherein Y1, Y2, Ar1, Ar2, R1, R2, i, j, k, l are as defined in claim 1.

Abstract: Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).

Abstract: Novel grafted dinuclear metal complexes having formula (I) or of formula (II) wherein M represents a metal ion, and also the use thereof as sensors in a method for detecting and/or characterising cellular microparticles.

Abstract: The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.

Abstract: This invention relates to a method for producing functionalized telechelic oligomers, comprising two steps. The first step relates to bringing a raw material comprising at least one high-molecular-weight polymer comprising at least two unsaturations, into contact with a solution comprising at least one metathesis catalyst and at least one functionalizing agent. The second step relates to the separation of the functionalized telechelic oligomers produced by the metathesis reaction in ionic liquid medium of the first step.

Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.

Abstract: Compounds are provided according to Formula (I) as well as their enantiomers and their racemics, their acid salts, their hydrates or their solvation products. Among a large number of possible meanings, X represents a halogen, Y an oxygen atom; all of the coefficients m, n, r and s have the value 1, R represents an ethyl and R? a cycloalkyl. The invention also includes Methods of preparing the above compounds and the pharmaceutical compositions containing them also are provided.

Abstract: The invention relates to compounds of formula (I), and to their therapeutic use in the treatment of cancer: Wherein Y1, Y2, Ar1, Ar2, R1, R2, i, j, k, l are as defined in claim 1.

Abstract: Novel grafted dinuclear metal complexes having formula (I) or of formula (II) wherein M represents a metal ion, and also the use thereof as sensors in a method for detecting and/or characterising cellular microparticles.

Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.

Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.

Abstract: The present invention relates to reducible porous crystalline solids, constituted of a metal-organic framework (MOF), for the separation of mixtures of molecules having different unsaturation degrees and/or a different number of unsaturations with a selectivity that can be adjusted by controlling the reduction of the MOF. The MOF solids of the present invention, after reduction, have a strong affinity for molecules containing at least one unsaturation. They can be used in various separation processes, especially those relating to hydrocarbons.

Abstract: The invention relates to a method for measuring the plasmine activity of microparticles, in particular circulating microparticles, in a sample of a biological fluid, particularly a biological fluid in a flow situation, wherein said method can be used as a diagnosis method or a method for following a treatment.

Abstract: A method of generating a pseudorandom data sequence, wherein said pseudorandom data sequence is generated by a procedure for searching for a search pattern in an initial data sequence of N bits, said search procedure comprising the following steps: (a) detecting in said initial data sequence a particular search pattern of r bits that is one of a set of search patterns; (b) determining an output pattern of k bits by an operation that depends on the progress of the preceding step; and repeating the preceding steps (a) and (b) successively to form the pseudorandom data sequence from a succession of output patterns.

Abstract: The present invention relates to reducible porous crystalline solids, constituted of a metal-organic framework (MOF), for the separation of mixtures of molecules having different unsaturation degrees and/or a different number of unsaturations with a selectivity that can be adjusted by controlling the reduction of the MOF. The MOF solids of the present invention, after reduction, have a strong affinity for molecules containing at least one unsaturation. They can be used in various separation processes, especially those relating to hydrocarbons.

Abstract: The compounds correspond to the general formula ##STR1## in which R.sub.1 represents a hydrogen atom or a group --COR.sub.2, in which R.sub.2 represents a benzene ring, cyclopentylmethyl, cyclohexylmethyl, cyclopentylethyl or cyclohexylethyl groups or cyclopentylamine, cyclohexylamine or phenylamine, chlorophenylamine or dichlorophenylamine groups; R represents a hydrogen atom or a group COR.sub.3, in which R.sub.3 represents an aliphatic group, a cyclane or benzene ring-system, a group a group (CH.sub.2).sup.m R.sub.4, a group --CH.dbd.CHR.sub.8 or a secondary amine group --NH(CH.sub.2).sub.n R.sub.

Abstract: Compounds of general formula ##STR1## in which R.sub.1 denotes H, CH.sub.3 or C.sub.2 H.sub.5, R denotes H or R.sub.2 and R.sub.2 denotes an alkyl, piperonyl, 3-(1-benzimidazolonyl)-propyl group; a group of formula ##STR2## in which n is 0, 1, 2, or 3, X is a single bond or alternatively --O--, --S--, --NH--, --CO--, --CH.dbd.CH-- or ##STR3## and R.sub.3 is H, CH.sub.3, F, CN or an acyl group; or alternatively a group of formula ##STR4## in which Z denotes an O or S atom or a divalent group NH, N --CH.sub.3 or N --CN, and R.sub.5 denotes an alkyl group, a cycloalkyl group which can bear a phenyl substituent, a phenyl group which can bear a CH.sub.3 or F substituent, a phenylalkyl(1-3 C) group or a naphthyl, adamantyl or p-toluenesulphonyl group. These compounds are useful to control the release of cerebral histamine and to increase the rate of renewal of cerebral histamine.